Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE PD01A With Regard to Safety/Tolerability, Immunological Plus Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008

Trial Profile

Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE PD01A With Regard to Safety/Tolerability, Immunological Plus Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Affitope PD01 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors AFFiRiS
  • Most Recent Events

    • 07 Sep 2016 Results (n=28) published in an AFFiRiS media release.
    • 07 Sep 2016 According to an AFFiRiS media release, this study was funded by a $US1.04 million grant from the Michael J. Fox Foundation for Parkinson's research.
    • 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top